Antibody-specific behavioral effects: Intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice

Journal of Neuroimmunology

Volumn 272, Issue 1-2, 2014, Pages 10-15

  Katzav, Aviva ^a,b   Ben Ziv, Tal ^b   Blank, Miri ^b   Pick, Chaim G ^b   Shoenfeld, Yehuda ^b   Chapman, Joab ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoantibodies; Behavior; Cognitive function; Depression; Experimental mouse model; Smell

Indexed keywords

ANTIBODY; PHOSPHOLIPID ANTIBODY; RIBOSOMAL P ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BEHAVIOR DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; EXPERIMENTAL MODEL; FEMALE; HYPERACTIVITY; MENTAL PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMELLING DISORDER; TASK PERFORMANCE;

AUTOANTIBODIES; BEHAVIOR; COGNITIVE FUNCTION; DEPRESSION; EXPERIMENTAL MOUSE MODEL; SMELL;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AVOIDANCE LEARNING; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERKINESIS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENTRICULAR; MAZE LEARNING; MICE; MICE, INBRED BALB C; OLFACTION DISORDERS; PSYCHOMOTOR PERFORMANCE; RIBOSOMAL PROTEINS; SENSORY THRESHOLDS; SMELL;

EID: 84902014382     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.04.003     Document Type: Article

References (51)

1. Ainiala H., Loukkola J., Peltola J., Korpela M., Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
2. Amigo M.C., Khamashta M.A., Hughes G.R. Antiphospholipid syndrome in SLE. Baillieres Clin. Rheumatol. 1998, 12:477-493.
3. Arnson Y., Shoenfeld Y., Alon E., Amital H. The antiphospholipid syndrome as a neurological disease. Semin. Arthritis Rheum. 2010, 40:97-108.
4. Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D., Stallworth C.L., Valdez C.R., Escalante A., del Rincon I., Gronseth G., Rhine C.B., Padilla P., McGlasson D. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214-1220.
5. Caponi L., Anzilotti C., Longombardo G., Migliorini P. Antibodies directed against ribosomal P proteins cross-react with phospholipids. Clin. Exp. Immunol. 2007, 150:140-143.
6. Caronti B., Calderaro C., Alessandri C., Conti F., Tinghino R., Pini C., Palladini G., Valesini G. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun. 1998, 11:425-429.
7. Colasanti T., Delunardo F., Margutti P., Vacirca D., Piro E., Siracusano A., Ortona E. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J. Neuroimmunol. 2009, 212:3-9.
8. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
9. Denburg S.D., Denburg J.A. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 2003, 12:883-890.
10. Diamond B. Antibodies and the brain: lessons from lupus. J. Immunol. 2010, 185:2637-2640.
11. Eber T., Chapman J., Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?. Lupus 2005, 14:571-575.
12. Efthimiou P., Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod. Rheumatol. 2009, 19:457-468.
13. Elkon K.B., Bonfa E., Brot N. Antiribosomal antibodies in systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 1992, 18:377-390.
14. Faust T.W., Chang E.H., Kowal C., Berlin R., Gazaryan I.G., Bertini E., Zhang J., Sanchez-Guerrero J., Fragoso-Loyo H.E., Volpe B.T., Diamond B., Huerta P.T. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18569-18574.
15. Ghirardello A., Doria A., Zampieri S., Gerli R., Rapizzi E., Gambari P.F. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann. Rheum. Dis. 2000, 59:975-981.
16. Hanly J.G., Hong C., Smith S., Fisk J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999, 42:728-734.
17. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., Chapman J. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
18. Katzav A., Chapman J., Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003, 12:903-907.
19. Katzav A., Litvinjuk Y., Pick C.G., Blank M., Shoenfeld Y., Sirota P., Chapman J. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav. Brain Res. 2006, 169:289-293.
20. Katzav A., Solodeev I., Brodsky O., Chapman J., Pick C.G., Blank M., Zhang W., Reichlin M., Shoenfeld Y. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 2007, 56:938-948.
21. Katzav A., Ben-Ziv T., Chapman J., Blank M., Reichlin M., Shoenfeld Y. Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J. Autoimmun. 2008, 31:393-398.
22. Katzav A., Shoenfeld Y., Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 2010, 38:196-200.
23. Katzav A., Faust-Socher A., Kvapil F., Michaelson D.M., Blank M., Pick C.G., Shoenfeld Y., Korczyn A.D., Chapman J. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol. Aging 2011, 32:272-279.
24. Kiss E., Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus?. Clin. Rev. Allergy Immunol. 2007, 32:37-46.
25. Kivity S., Katzav A., Arango M.T., Landau-Rabi M., Zafrir Y., Agmon-Levin N., Blank M., Anaya J.M., Mozes E., Chapman J., Shoenfeld Y. 16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus. BMC Med. 2013, 11:90.
26. Koren E., Reichlin M.W., Koscec M., Fugate R.D., Reichlin M. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J. Clin. Invest. 1992, 89:1236-1241.
27. Koscec M., Koren E., Wolfson-Reichlin M., Fugate R.D., Trieu E., Targoff I.N., Reichlin M. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J. Immunol. 1997, 159:2033-2041.
28. Kozora E., Hanly J.G., Lapteva L., Filley C.M. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum. 2008, 58:3286-3298.
29. Love P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med. 1990, 112:682-698.
30. Lumia A.R., Teicher M.H., Salchli F., Ayers E., Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res. 1992, 587:181-185.
31. Matus S., Burgos P.V., Bravo-Zehnder M., Kraft R., Porras O.H., Farias P., Barros L.F., Torrealba F., Massardo L., Jacobelli S., Gonzalez A. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J. Exp. Med. 2007, 204:3221-3234.
32. Menachem A., Chapman J., Katzav A. Hyperactivity induced by antiphospholipid syndrome serum. Ann. N. Y. Acad. Sci. 2009, 1173:422-426.
33. Mucignat-Caretta C., Bondi M., Caretta A. Animal models of depression: olfactory lesions affect amygdala, subventricular zone, and aggression. Neurobiol. Dis. 2004, 16:386-395.
34. Muscal E., Brey R.L. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus 2010, 19:406-411.
35. Pause B.M., Miranda A., Goder R., Aldenhoff J.B., Ferstl R. Reduced olfactory performance in patients with major depression. J. Psychiatr. Res. 2001, 35:271-277.
36. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
37. Reichlin M. Autoantibodies to the ribosomal P proteins in systemic lupus erythematosus. Clin. Exp. Med. 2006, 6:49-52.
38. Sanna G., D'Cruz D., Cuadrado M.J. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum. Dis. Clin. N. Am. 2006, 32:465-490.
39. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 2004, 34:501-537.
40. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., Pick C.G., Leider-Trejo L., Kalashnikova L., Blank M., Chapman J. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
41. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., Blank M., Zaech J., Shoenfeld Y., Sirota P., Chapman J. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
42. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 2005, 29:627-647.
43. Stafford H.A., Chen A.E., Anderson C.J., Paul A.G., Wyatt E.L., Lee L.A., Neas B.R. Anti-ribosomal and 'P-peptide'-specific autoantibodies bind to T lymphocytes. Clin. Exp. Immunol. 1997, 109:12-19.
44. Sun K.H., Tang S.J., Lin M.L., Wang Y.S., Sun G.H., Liu W.T. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001, 40:750-756.
45. Tanne D., Katzav A., Beilin O., Grigoriadis N.C., Blank M., Pick C.G., Landenberg P., Shoenfeld Y., Chapman J. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol. Dis. 2008, 30:56-64.
46. Teh L.S., Isenberg D.A. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum. 1994, 37:307-315.
47. Tincani A., Andreoli L., Chighizola C., Meroni P.L. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 2009, 42:257-259.
48. Toubi E., Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun. Rev. 2007, 6:119-125.
49. Unterman A., Nolte J.E., Boaz M., Abady M., Shoenfeld Y., Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin. Arthritis Rheum. 2011, 41:1-11.
50. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin. Arthritis Rheum. 2007, 36:297-315.
51. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J. Clin. Invest. 1997, 100:613-619.